Johnson & Johnson's MonumenTAL-6: Tecvayli+Talvey Cuts Myeloma Progression Risk 89%, Death 62%
Johnson & Johnson released phase 3 MonumenTAL-6 data showing that the combination of bispecific antibodies Tecvayli and Talvey reduced the risk of disease progression or death by 89% and the risk of death by 62% in patients with multiple myeloma who had received two to five prior lines of therapy. The trial enrolled patients previously treated with a CD38 antibody, with about 80% being resistant to daratumumab. The first interim analysis met both progression-free survival and overall survival endpoints.